UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Its Charter)
|
| |||
(State or Other Jurisdiction | (Commission | (I.R.S. Employer |
(Address of Principal Executive Offices) | (Zip Code) |
| ( |
|
(Registrant’s Telephone Number, Including Area Code) |
| N/A |
|
(Former Name or Former Address, if Changed Since |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻
Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On May 12, 2023, Eric J. Ende, M.D. notified NeuBase Therapeutics, Inc. (the “Company”) of his resignation from the Board of Directors (the “Board”) of the Company, effective May 12, 2023. Dr. Ende served as a member of the Nominating and Corporate Governance Committee of the Board and the Compensation Committee of the Board. Dr. Ende’s resignation is not a result of any disagreement with the Company on any matter relating to the Company’s policies or procedures.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| NEUBASE THERAPEUTICS, INC. | |
|
| |
Date: May 18, 2023 | By: | /s/ Todd P. Branning |
|
| Todd P. Branning |
|
| Chief Financial Officer |
Document and Entity Information |
May 12, 2023 |
---|---|
Document and Entity Information [Abstract] | |
Document Type | 8-K |
Document Period End Date | May 12, 2023 |
Entity File Number | 001-35963 |
Entity Registrant Name | NeuBase Therapeutics, Inc. |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 46-5622433 |
Entity Address State Or Province | PA |
Entity Address, Address Line One | 350 Technology Drive |
Entity Address, City or Town | Pittsburgh |
Entity Address, Postal Zip Code | 15219 |
City Area Code | 412 |
Local Phone Number | 763-3350 |
Title of 12(b) Security | Common Stock, par value $0.0001 per share |
Trading Symbol | NBSE |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Entity Central Index Key | 0001173281 |
Amendment Flag | false |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
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end
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